Pulmonary Drug Delivery Systems Market Snapshot
|Fastest Growing Market:||Asia Pacific|
|Largest Market:||North America|
Need a report that reflects how COVID-19 has impacted this market and its growth?
The Pulmonary Drug Delivery Systems Market is expected to register a CAGR of 4% during the forecast period.
Coronavirus disease 2019 (COVID-19) is a primary respiratory infectious disease, which can result in pulmonary and cardiovascular complications. As per an article titled “Pulmonary Hypertension (PH) and COVID-19” published in August 2022 by Hamostaseologie, echocardiographic signs of PH in approximately 12 to 13% of hospitalized patients with COVID-19. Those with chronic pulmonary obstructive disease, congestive heart failure, pulmonary embolism, and prior PH are at increased risk to develop or worsen pulmonary hypertension (PH). Evidence of PH seems to be associated with increased disease severity and poor outcome. Because of the importance of pulmonary hemodynamics in the pathophysiology of COVID-19, there is growing interest in exploring the potential therapeutical benefits of inhaled vasodilators in patients with COVID-19.
As per an article titled “Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective” published in December 2021, the dynamic behavior of the SARS-CoV-2 virus and the potential causes of heterogeneity in COVID-19 are essential for anticipating and treating the disease, in both the acute and the chronic stages, including the development of chronic pulmonary hypertension. Both COVID-19 and chronic pulmonary diseases have assumed global dimensions, with potentially complex interactions. Therefore, COVID-19 is said to have a significant impact on the market during the pandemic.
The market is expected to see a surge due to technological advancements, increasing incidence of respiratory diseases, increasing preference for pulmonary drug delivery as an alternate route of drug delivery. Pulmonary drug delivery systems are ideal drug approaches compared to conventional drug delivery approaches due to several advantages associated with this delivery system such as huge surface area present in alveolar sacs, high drug loading efficiency, and high vascularization which makes the lung appropriate site for drug absorption.
Moreover, increasing incidences of chronic respiratory diseases will surge the demand for a pulmonary drug delivery system. As stated by the data from the World Health Organization in 2021, chronic respiratory diseases affect more than one billion people globally. Additionally, as per the data from Lung India as of August 2022, the prevalence of asthma among Indian children was around 18.2%. Therefore, the increasing prevalence of respiratory diseases has augmented the demand for early treatment, which is expected to increase the sales of pulmonary drug delivery system.
Moreover, as per an article titled “Prevalence, incidence, and survival of pulmonary arterial hypertension: A systematic review for the global burden of disease 2020 study” published in January 2022, pulmonary arterial hypertension (PAH) is characterized by increased resistance in the pulmonary arterioles because of remodeled blood vessels. The prevalence ranged from 0.4 to 1.4 per 100,000 persons. Moreover, some of the major preventable chronic respiratory disorders are asthma, chronic obstructive pulmonary disease (COPD), allergic rhinitis, sleep apnea, and tuberculosis (principally, multi-drug resistant tuberculosis). As per the Asthma and allergy foundation of America published in March 2021, Roughly 1 in 13 Americans have asthma, which is about 25 million people. Asthma is one of the largest contributors to this figure, affecting children, adults, and elderly people. The same source stated that about 5 million American children have asthma. There is a high prevalence of severe asthma in the Middle East & Africa and the Latin America region as compared to the mid-range of prevalence in North America, Europe, and Asia-Pacific countries.
Thus, all the aforementioned factors are expected to boost market growth over the forecast period. However, regulatory issues may restrain the market's growth over the forecast period.
Scope of the Report
As per the scope, Pulmonary drug delivery systems deal with delivering the drug to the lung for the treatment of respiratory diseases. It is a non-invasive technique in which there is a large surface area of absorption and blood circulation, the permeability rate is higher which makes this technique an ideal method for the treatment of respiratory diseases. The Pulmonary Drug Delivery Systems Market is segmented By Product (Dry Powder Inhalers, Metered Dose Inhalers, Nebulizers), By Application (Cystic Fibrosis, Asthma, Allergic Rhinitis, COPD, and Others), By End User (Hospitals, Diagnostic Centers, and Others), Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.
|Dry Powder Inhalers|
|Metered Dose Inhalers|
|By End User|
Key Market Trends
Pulmonary Drug Delivery Systems in Asthma is Estimated to Witness a Healthy Growth in Future.
Pulmonary Drug Delivery Systems in asthma is estimated to witness healthy growth in the future which is attributed to an increasing number of populations affected by asthma and the high adoption of metered-dose inhalers (MDI) and dry powder inhaler (DPI) for asthmatic patients. Benefits associated with these devices such as cost-effectiveness, high acceptance rate, short administration and preparation time, and technological advancements make these devices highly preferable for the treatment of several types of respiratory diseases.
According to the World Health Organization (WHO) 2021 factsheet, asthma is a major non-communicable disease (NCD), affecting both children and adults. Globally, it affected an estimated 262 million. Also, as per the European Respiratory Society’s (ERS) research study titled "An estimate of the European prevalence of COPD in 2050", published in 2020, ERS estimated that there were 36,580,965 Europeans with COPD, and the number is projected to reach 49,453,852 people by the year 2050. Moreover, as per another article titled “The Incidence and Prevalence of Pulmonary Hypertension in the COPD Population: A Systematic Review and Meta-Analysis” published in February 2022, the global incidence of PH in the Chronic obstructive pulmonary disease (COPD) population is very high, and there are significant regional and international variations. Thus, the high cases of pulmonary disaeases are expected to boost the growth of the market segment over the forecast period.
Thus, these aforementioned factors are collectively driving the growth of the segment throughout the forecast period.
To understand key trends, Download Sample Report
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America is expected to hold a significant market share in the pulmonary drug delivery systems market due to the rising geriatric population, presence of key pharmaceuticals and medical device players, changing lifestyles, increasing healthcare expenditure, and high disposable income. Moreover, increasing incidences of COPD and asthma and growing demand for diagnostic devices will also boost the market in this region.
According to the Asthma and Allergy Foundation of America (AAFA), in 2021, roughly 1 in 13 Americans had asthma, which is about 25 million people. As per the same source, about 5 million American children have asthma. Moreover, according to the Centers for Disease Control and Prevention 2020 report, in the United States, approximately 25 million Americans have asthma. This equals to about 1 in 13 Americans, including 8% of adults and 7% of children. About 20 million United States adults aged 18 years and over have asthma. Similarly, asthma is a major public health concern in Canada. As a lifelong respiratory illness, asthma affects the work productivity, quality of life, mental health, and psychological well-being of the Canadian population. The high number of patients affected by asthma increases the demand for drugs for the treatment of the target disease and also the delivery of its drug, thereby boosting the growth of this region.
In addition, according to the study titled "Respiratory Symptoms among US Adults: a Cross-Sectional Health Survey Study" published in the Pulmonary Therapy in July 2022, the most common respiratory symptom, followed by a productive cough and shortness of breath, affects 17% of adult Americans. Thus, with the growing burden of respiratory diseases, the demand for pulmonary drug delivery systems is expected to increase over the forecast period, thereby boosting the market's growth.
Thus, the aforementioned factors are expected to drive the market's growth over the forecast period.
To understand geography trends, Download Sample Report
The Pulmonary Drug Delivery Systems Market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are Koninklijke Philips N.V, GlaxoSmithKline plc., 3M, Novartis AG, Boehringer Ingelheim International GmbH, AstraZeneca, Cipla Inc, Merck & Co., and GF Health Products, Inc.\
Koninklijke Philips N.V
Boehringer Ingelheim International GmbH
- In September 2022, RIGImmune signed a deal to acquire Subintro, giving it access to novel topical delivery systems. The deal positions the biotech to advance the development of novel RNA therapies and vaccine adjuvants for local mucosal delivery.
- In August 2022, Aptar Pharma acquired Orbital Dry Powder Inhaler (DPI) worldwide license. This acquisition will help Aptar Pharma meet the growing global demand for safe and convenient administration of high-dose treatments to the lungs.
Table of Contents
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Technological Advancements
4.2.2 Increasing Incidence of Respiratory Diseases
4.2.3 Increasing Preference for Pulmonary Drug Delivery as an Alternate Route of Drug Delivery
4.3 Market Restraints
4.3.1 Regulatory Issues
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD Million)
5.1 By Product
5.1.1 Dry Powder Inhalers
5.1.2 Metered Dose Inhalers
126.96.36.199 Jet Nebulizers
188.8.131.52 Soft Mist Nebulizers
184.108.40.206 Ultrasonic Nebulizers
5.2 By Application
5.2.1 Cystic Fibrosis
5.2.3 Allergic Rhinitis
5.3 By End User
5.3.2 Diagnostic Centers
5.4.1 North America
220.127.116.11 United States
18.104.22.168 United Kingdom
22.214.171.124 Rest of Europe
126.96.36.199 South Korea
188.8.131.52 Rest of Asia-Pacific
5.4.4 Middle East and Africa
184.108.40.206 South Africa
220.127.116.11 Rest of Middle-East and Africa
5.4.5 South America
18.104.22.168 Rest of South America
6. COMPETITIVE LANDSCAPE
*List Not Exhaustive
6.1 Company Profiles
6.1.1 Koninklijke Philips N.V
6.1.2 GlaxoSmithKline plc.
6.1.4 Novartis AG
6.1.5 Boehringer Ingelheim International GmbH
6.1.7 Cipla Inc
6.1.8 Merck & Co.
6.1.9 GF Health Products, Inc.
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Frequently Asked Questions
What is the study period of this market?
The Global Pulmonary Drug Delivery Systems Market market is studied from 2019 - 2027.
What is the growth rate of Global Pulmonary Drug Delivery Systems Market?
The Global Pulmonary Drug Delivery Systems Market is growing at a CAGR of 4% over the next 5 years.
Which region has highest growth rate in Global Pulmonary Drug Delivery Systems Market?
Asia Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Global Pulmonary Drug Delivery Systems Market?
North America holds highest share in 2021.
Who are the key players in Global Pulmonary Drug Delivery Systems Market?
Koninklijke Philips N.V, 3M, Novartis AG, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc. are the major companies operating in Global Pulmonary Drug Delivery Systems Market.